Related Experiment Video

Updated: Apr 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer

Brock E Boehm1, Robert S Svatek1

  • 1Adult Cancer Program, Department of Urology, Cancer Therapy and Research Center, The University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78023, USA.

The Urologic Clinics of North America
|April 18, 2015
PubMed

Insights

Novel strategies for nonmuscle invasive bladder cancer focus on improving intravesical agent delivery and utilizing immune-based therapies like vaccines and checkpoint inhibitors for better bladder cancer treatment.

Area of Science:

  • Oncology
  • Urology

Background:

  • Nonmuscle invasive bladder cancer (NMIBC) treatment faces challenges with intravesical agent efficacy.
  • Limited contact time of intravesical agents in the bladder restricts therapeutic effectiveness.

Purpose of the Study:

  • To summarize emerging strategies for NMIBC treatment.
  • To highlight advancements in intravesical therapy delivery and novel immune-based approaches.

Main Methods:

  • Review of current and investigational strategies for NMIBC.
  • Focus on improving intravesical agent delivery methods.
  • Exploration of immune-based therapies including vaccines, Bacillus Calmette-Guérin (BCG) subcomponents, and checkpoint inhibitors.
  • Investigation of direct intravesical delivery of gene therapy via catheterization.

Main Results:

  • Progress in enhancing the retention of intravesical agents within the bladder.
  • Identification of bladder cancer's responsiveness to immunotherapy.
  • Development of novel immune-based therapies showing promise.
  • Emergence of gene therapy delivery strategies via catheterization.

Conclusions:

  • Optimizing intravesical agent delivery is crucial for NMIBC management.
  • Immune-based therapies represent a significant advancement in bladder cancer treatment.
  • Direct intravesical delivery offers new avenues for targeted cancer therapy.
Keywords:
BladderCancerNovelTherapeutics

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.3K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K